On April 9, 2026, Ryan Savitz, who serves as Executive Vice President, Chief Financial Officer and Chief Business Officer of Dianthus Therapeutics (NASDAQ: DNTH), sold 8,224 shares of the companys common stock for aggregate proceeds of $738,844. The transaction was carried out at a weighted average price of $89.84 per share, with executed prices ranging from $89.75 to $89.95.
Concurrently on the same date, Savitz exercised options to acquire 8,224 shares of Dianthus common stock at an exercise price of $17.88 per share, representing a total exercise amount of $147,045. Both the sale and the option exercise were implemented under a pre-arranged Rule 10b5-1 trading arrangement that Savitz adopted on December 30, 2025.
Following the completion of these transactions, Savitz no longer directly holds any Dianthus common stock.
Independent platform analysis cited in the companys reporting indicates that, at present, the stock appears overvalued relative to its Fair Value. That analysis is accompanied by a set of additional commentary and guidance items, listed as 15 ProTips on the platform, that provide further financial and market context for DNTH.
These insider transactions occurred against a backdrop of material capital markets activity at Dianthus. The company disclosed the closing of an underwritten public offering that raised approximately $719 million in gross proceeds. As part of that offering, Dianthus sold 8,470,989 shares of common stock at $81.00 per share, which included the full exercise of the underwriters option to purchase additional shares. In connection with the deal, Dianthus also issued pre-funded warrants to purchase up to 402,468 shares at a per-warrant price of $80.999.
Market and clinical observers also had fresh data points to consider. William Blair reiterated its Outperform rating on Dianthus after an FDA update removed antinuclear antibodies as a screening criterion for the companys claseprubart clinical trials, a change described as addressing concerns about drug-induced lupus within that development program. Separately, William Blair cited interim results from the CAPTIVATE trial in chronic inflammatory demyelinating polyneuropathy, noting competitive efficacy and safety findings as a rationale for its stance. Wells Fargo likewise maintained an Overweight rating on the company, retaining a price target of $135.00.
Taken together, the insider sale and option exercise, the recent capital raise, and the analyst reiterations following regulatory and trial updates underline ongoing investor and analyst engagement with Dianthuss clinical and financing trajectory. The company remains an active subject of market attention as capital markets, clinical development, and analyst coverage converge on the stock.